Table 2.
Promising epitope-based universal influenza vaccines at clinical trials.
| Vaccine | Company | Projects | Clinical Phase | Clinical Trial Registration# | Reference | ||
|---|---|---|---|---|---|---|---|
| I | II | III | |||||
| FP-01.1 | Immune Targeting Systems Ltd., London, UK. | FP-01.1 | completed | completed | NCT01265914, NCT01677676, NCT02071329 | Francis 2015 [80] | |
| FP-01.1-Adjuvant | completed | NCT01677676 | unpublished | ||||
| FP-01.1 + seasonal TIV + FP-01.1-Adjuvant | completed | NCT01701752 | unpublished | ||||
| Flu-v | PepTcell Limited | Flu-v | completed | NCT01226758, NCT01181336 | Pleguezuelos 2015 [82] | ||
| adjuvanted Flu-v | completed | NCT03180801, NCT02962908 | van Doorn 2017 [83] | ||||
| Multimeric-001 (M-001) | BiondVax Pharmaceuticals Ltd | M-001 | completed | completed | NCT01146119, NCT01010737 | Atsmon 2014 [86] | |
| M-001 (prime) + seasonal TIV vaccine (boost) | completed | completed | NCT03058692, NCT01419925, NCT02293317 | Atsmon 2014 [86] | |||
| M-001 (prime) + H5N1 vaccine (boost) | completed | completed | NCT02691130 | unpublished | |||
| M-001 as standalone vaccine | ongoing | NCT03450915 | unpublished | ||||